~~<i id='94B5502077'><strike id='94B5502077'><tt id='94B5502077'><pre id='94B5502077'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：leisure time 2025-10-06 08:58:36 Page View：687

Editor’s note: A recording of the event is embedded below.

After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

Featured Speakers

Irena Melnikova, Ph.D., partner, Pfizer Ventures
Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Obesity now affects over 1 billion people worldwide, study finds
Next article： ChatGPT in medicine: STAT answers readers' burning questions

explore

The high cost of giving birth even with insurance

AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

Biden warns of ‘dark winter’ during final presidental debate

DemocraticpresidentialcandidateformerVicePresidentJoeBidenanswersaquestionasPresidentTrumplistensdur

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Rise in cancer among younger people worries and puzzles doctors

Atumorinvasionintoaveininacaseofcolorectalcancer.WikimediaCommonsWhenboththenurseandthe doctorbroked